Literature DB >> 15721644

Analysis of somatic NF1 promoter methylation in plexiform neurofibromas and Schwann cells.

Lauren Fishbein1, Bonnie Eady, Nicholas Sanek, David Muir, Margaret R Wallace.   

Abstract

Neurofibromatosis 1 (NF1) is an autosomal dominant disorder with the characteristic feature being the neurofibroma. It is believed that both NF1 alleles must be inactivated as the first step in tumorigenesis. However, often the somatic mutations are not identified, suggesting that epigenetic changes such as methylation could account for the "second hit" in some tumors. The literature reports that the region of the NF1 promoter surrounding the transcription start site is completely unmethylated in several normal tissues and some NF1-related dermal and plexiform neurofibromas. We analyzed the methylation state of the NF1 promoter in normal Schwann cells (the cell type clonally expanded in neurofibromas) and in NF1-related plexiform tumor samples with unidentified somatic mutations. In a region of 451 bp surrounding the transcription start site, a low level of methylation was found at several specific cytosines in 12 of 18 tumor samples. Overall, epigenetic silencing through methylation does not appear to be a major mechanism for the second hit. However, this study, which analyzed the largest number of NF1-related plexiform tumors and is the first to include Schwann cell-enriched tumor cultures, detected greater methylation than in any previous reports. This suggests that methylation, especially at potential transcription factor binding sites, is moderately perturbed in some plexiform neurofibromas and should be investigated further.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15721644     DOI: 10.1016/j.cancergencyto.2004.08.016

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  10 in total

1.  Molecular diagnosis of neurofibromatosis type 1: 2 years experience.

Authors:  Siân Griffiths; Peter Thompson; Ian Frayling; Meena Upadhyaya
Journal:  Fam Cancer       Date:  2007       Impact factor: 2.375

2.  Analysis of NF1 somatic mutations in cutaneous neurofibromas from patients with high tumor burden.

Authors:  Laura Thomas; Lan Kluwe; Nadia Chuzhanova; Victor Mautner; Meena Upadhyaya
Journal:  Neurogenetics       Date:  2010-04-01       Impact factor: 2.660

3.  Exploring the somatic NF1 mutational spectrum associated with NF1 cutaneous neurofibromas.

Authors:  Laura Thomas; Gill Spurlock; Claire Eudall; Nick S Thomas; Matthew Mort; Stephen E Hamby; Nadia Chuzhanova; Hilde Brems; Eric Legius; David N Cooper; Meena Upadhyaya
Journal:  Eur J Hum Genet       Date:  2011-11-23       Impact factor: 4.246

Review 4.  The pathoetiology of neurofibromatosis 1.

Authors:  Eeva-Mari Jouhilahti; Sirkku Peltonen; Anthony M Heape; Juha Peltonen
Journal:  Am J Pathol       Date:  2011-03-31       Impact factor: 4.307

5.  Analysis of steroid hormone effects on xenografted human NF1 tumor schwann cells.

Authors:  Hua Li; Xuelian Zhang; Lauren Fishbein; Frederick Kweh; Martha Campbell-Thompson; George Q Perrin; David Muir; Margaret Wallace
Journal:  Cancer Biol Ther       Date:  2010-10-15       Impact factor: 4.742

6.  Comparative methylome analysis of benign and malignant peripheral nerve sheath tumors.

Authors:  Andrew Feber; Gareth A Wilson; Lu Zhang; Nadege Presneau; Bernadine Idowu; Thomas A Down; Vardhman K Rakyan; Luke A Noon; Alison C Lloyd; Elia Stupka; Vassia Schiza; Andrew E Teschendorff; Gary P Schroth; Adrienne Flanagan; Stephan Beck
Journal:  Genome Res       Date:  2011-02-01       Impact factor: 9.043

7.  Somatic neurofibromatosis type 1 (NF1) inactivation characterizes NF1-associated pilocytic astrocytoma.

Authors:  David H Gutmann; Michael D McLellan; Ibrahim Hussain; John W Wallis; Lucinda L Fulton; Robert S Fulton; Vincent Magrini; Ryan Demeter; Todd Wylie; Cyriac Kandoth; Jeffrey R Leonard; Abhijit Guha; Christopher A Miller; Li Ding; Elaine R Mardis
Journal:  Genome Res       Date:  2012-12-05       Impact factor: 9.043

8.  Methylated RASSF1A in malignant peripheral nerve sheath tumors identifies neurofibromatosis type 1 patients with inferior prognosis.

Authors:  Stine A Danielsen; Guro E Lind; Matthias Kolberg; Maren Høland; Bodil Bjerkehagen; Kirsten Sundby Hall; Eva van den Berg; Fredrik Mertens; Sigbjørn Smeland; Piero Picci; Ragnhild A Lothe
Journal:  Neuro Oncol       Date:  2014-07-19       Impact factor: 12.300

9.  TAGLN expression is upregulated in NF1-associated malignant peripheral nerve sheath tumors by hypomethylation in its promoter and subpromoter regions.

Authors:  Gun-Hoo Park; Su-Jin Lee; Hyunee Yim; Jae-Ho Han; Hyon J Kim; Young-Bae Sohn; Jung Min Ko; Seon-Yong Jeong
Journal:  Oncol Rep       Date:  2014-08-04       Impact factor: 3.906

10.  Identification of a germline CSPG4 variation in a family with neurofibromatosis type 1-like phenotype.

Authors:  Zhuanli Bai; Yiping Qu; Lin Shi; Xinju Li; Zhen Yang; Meiju Ji; Peng Hou
Journal:  Cell Death Dis       Date:  2021-08-03       Impact factor: 8.469

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.